UCB Pharma GmbH
Schwarz Pharma AG:First Quarter Report 2007
SCHWARZ PHARMA AG / Quarter Results Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- First Quarter Report 2007 SCHWARZ PHARMA with a Good Start The SCHWARZ PHARMA Group achieved sales of €232.1 million in the first quarter of 2007. This marks a year-on-year decline of 6.2%. After adjusting for exchange rate effects, sales were down by 2.3%. Due to the decline in sales and a lower gross margin following a changed product profile, the operating result in the first quarter of 2007 fell to €9.9 million (-12.7%). The net result amounted to €3.2 million (previous year: €2.2 million) as a result of a declining tax burden. Corresponding earnings per share were €0.06 – in comparison to €0.05 per share in the previous year. SCHWARZ PHARMA Key Figures: January to March(IAS/IFRS; € million) Jan. – March Jan. – March Change in 2006 2007 % Net sales 247.4 232.1 -6.2 Research and development expense 45.8 44.2 -3.5 Operating result 11.4 9.9 -12.7 Net result 2.2 3.2 41.4 Cash flow from operating activities (21.5) (73.0) n.a.Outlook 2007: unchanged In fiscal year 2007, innovative drugs will not be able to offset significant sales declines. SCHWARZ PHARMA therefore expects sales to reach €800-850 million. Despite a high level of expenses, partly for restructuring, the company again seeks to achieve a positive net result. In this respect, the plan also includes product disposals or partnerships. You find more information on the internet: www.schwarzpharma.com SCHWARZ PHARMA AG is listed in the Prime Standard of the Frankfurter Wertpapierbörse (Frankfurt stock exchange) and member in the German stock index SDAX Security code no. 722 190 / ISIN no.: DE 0007221905 SCHWARZ PHARMA AG Alfred-Nobel-Str. 10 40789 Monheim Germany Corporate Communications: Antje Witte, Tel: +49 2173 48 1866 --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: 'We are satisfied with business development in the first quarter of 2007. The implemented restructuring measures, the continuing excellent launch of Neupro and the planned filing for three more indications are the best conditions for a successful year', said Detlef Thielgen, CEO of SCHWARZ PHARMA AG. Contact: Corporate Communications: Antje Witte, Tel: +49 2173 48 1866; DGAP 25.04.2007 ---------------------------------------------------------------------- Language: English Issuer: SCHWARZ PHARMA AG Alfred-Nobel-Str. 10 40789 Monheim Deutschland Phone: +49 2173 48 1866 Fax: +49 2173 48 1856 E-mail: antje.witte@schwarzpharma.com www: www.schwarzpharma.com ISIN: DE0007221905 WKN: 722190 Indices: SDAX, MIDCAP, PRIMEALL, CLASSICALLSHARE, CDAX, HDAX, GEX Listed: Amtlicher Markt in Frankfurt (Prime Standard), Düsseldorf; Freiverkehr in Berlin-Bremen, Hannover, Hamburg, München, Stuttgart End of News DGAP News-Service ---------------------------------------------------------------------------
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found